Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 80

1.

HER-2-directed, small-molecule antagonists.

Arkin M, Moasser MM.

Curr Opin Investig Drugs. 2008 Dec;9(12):1264-76. Review.

2.

Emerging treatments in oncology: focus on tyrosine kinase (erbB) receptor inhibitors.

Hamid O.

J Am Pharm Assoc (2003). 2004 Jan-Feb;44(1):52-8. Review.

PMID:
14965154
3.

Discovery of a novel Her-1/Her-2 dual tyrosine kinase inhibitor for the treatment of Her-1 selective inhibitor-resistant non-small cell lung cancer.

Cha MY, Lee KO, Kim JW, Lee CG, Song JY, Kim YH, Lee GS, Park SB, Kim MS.

J Med Chem. 2009 Nov 12;52(21):6880-8. doi: 10.1021/jm901146p.

PMID:
19888761
4.

Optimization of 6,7-disubstituted-4-(arylamino)quinoline-3-carbonitriles as orally active, irreversible inhibitors of human epidermal growth factor receptor-2 kinase activity.

Tsou HR, Overbeek-Klumpers EG, Hallett WA, Reich MF, Floyd MB, Johnson BD, Michalak RS, Nilakantan R, Discafani C, Golas J, Rabindran SK, Shen R, Shi X, Wang YF, Upeslacis J, Wissner A.

J Med Chem. 2005 Feb 24;48(4):1107-31.

PMID:
15715478
5.

Synthesis and biological evaluation of pyrimidine-based dual inhibitors of human epidermal growth factor receptor 1 (HER-1) and HER-2 tyrosine kinases.

Cha MY, Lee KO, Kang SJ, Jung YH, Song JY, Choi KJ, Byun JY, Lee HJ, Lee GS, Park SB, Kim MS.

J Med Chem. 2012 Mar 22;55(6):2846-57. doi: 10.1021/jm201758g. Epub 2012 Mar 9.

PMID:
22372864
6.

Targeting the HER-kinase axis in cancer.

Gross ME, Shazer RL, Agus DB.

Semin Oncol. 2004 Feb;31(1 Suppl 3):9-20. Review.

PMID:
15052539
8.

[Radiotherapy and inhibitors of epidermal growth factor receptor: preclinical findings and preliminary clinical trials].

Azria D, Larbouret C, Robert B, Culine S, Ychou M, Verrelle P, Dubois JB, Pèlegrin A.

Bull Cancer. 2003 Nov;90 Spec No:S202-12. Review. French.

PMID:
14763141
9.

Discovery of novel 5-alkynyl-4-anilinopyrimidines as potent, orally active dual inhibitors of EGFR and Her-2 tyrosine kinases.

Suzuki N, Shiota T, Watanabe F, Haga N, Murashi T, Ohara T, Matsuo K, Omori N, Yari H, Dohi K, Inoue M, Iguchi M, Sentou J, Wada T.

Bioorg Med Chem Lett. 2012 Jan 1;22(1):456-60. doi: 10.1016/j.bmcl.2011.10.103. Epub 2011 Nov 6.

PMID:
22101132
10.

Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase.

Rabindran SK, Discafani CM, Rosfjord EC, Baxter M, Floyd MB, Golas J, Hallett WA, Johnson BD, Nilakantan R, Overbeek E, Reich MF, Shen R, Shi X, Tsou HR, Wang YF, Wissner A.

Cancer Res. 2004 Jun 1;64(11):3958-65.

11.

The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: potential therapy for cancer.

Rusnak DW, Affleck K, Cockerill SG, Stubberfield C, Harris R, Page M, Smith KJ, Guntrip SB, Carter MC, Shaw RJ, Jowett A, Stables J, Topley P, Wood ER, Brignola PS, Kadwell SH, Reep BR, Mullin RJ, Alligood KJ, Keith BR, Crosby RM, Murray DM, Knight WB, Gilmer TM, Lackey K.

Cancer Res. 2001 Oct 1;61(19):7196-203.

12.
13.

Synergistic inhibition with a dual epidermal growth factor receptor/HER-2/neu tyrosine kinase inhibitor and a disintegrin and metalloprotease inhibitor.

Witters L, Scherle P, Friedman S, Fridman J, Caulder E, Newton R, Lipton A.

Cancer Res. 2008 Sep 1;68(17):7083-9. doi: 10.1158/0008-5472.CAN-08-0739.

14.

Human epidermal growth factor receptor (HER-1:HER-3) Fc-mediated heterodimer has broad antiproliferative activity in vitro and in human tumor xenografts.

Sarup J, Jin P, Turin L, Bai X, Beryt M, Brdlik C, Higaki JN, Jorgensen B, Lau FW, Lindley P, Liu J, Ni I, Rozzelle J, Kumari R, Watson SA, Zhang J, Shepard HM.

Mol Cancer Ther. 2008 Oct;7(10):3223-36. doi: 10.1158/1535-7163.MCT-07-2151.

15.

Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor.

Fry DW, Bridges AJ, Denny WA, Doherty A, Greis KD, Hicks JL, Hook KE, Keller PR, Leopold WR, Loo JA, McNamara DJ, Nelson JM, Sherwood V, Smaill JB, Trumpp-Kallmeyer S, Dobrusin EM.

Proc Natl Acad Sci U S A. 1998 Sep 29;95(20):12022-7.

16.

Development of natural product-derived receptor tyrosine kinase inhibitors based on conservation of protein domain fold.

Kissau L, Stahl P, Mazitschek R, Giannis A, Waldmann H.

J Med Chem. 2003 Jul 3;46(14):2917-31.

PMID:
12825933
17.

Drug discovery conference 2008. Small-Molecule Drug Discovery: From Early Stage to the Clinic.

Terrett NK.

IDrugs. 2008 Mar;11(3):164-8. No abstract available.

PMID:
18311648
18.
19.

ErbB-inhibitory protein: a modified ectodomain of epidermal growth factor receptor synergizes with dasatinib to inhibit growth of breast cancer cells.

Nautiyal J, Yu Y, Aboukameel A, Kanwar SS, Das JK, Du J, Patel BB, Sarkar FH, Rishi AK, Mohammad RM, Majumdar AP.

Mol Cancer Ther. 2010 Jun;9(6):1503-14. doi: 10.1158/1535-7163.MCT-10-0019. Epub 2010 Jun 1. Erratum in: Mol Cancer Ther. 2010 Sep;9(9):2637.

20.

CI-1033, a pan-erbB tyrosine kinase inhibitor.

Slichenmyer WJ, Elliott WL, Fry DW.

Semin Oncol. 2001 Oct;28(5 Suppl 16):80-5. Review.

PMID:
11706399

Supplemental Content

Support Center